Acute Myeloid Leukemia

Aggressiveness of acute myeloid leukemia elucidated

Antoine Peters and colleagues at the Basel University Children's Hospital (UKBB) have discovered why acute leukemias with the same genetic abnormality vary in their aggressiveness based on their cellular origin. They found ...

23 hours ago
popularity2 comments 0

Putting a brake on leukemia cells

Cancer cells need a lot of energy in order to divide without limits. Researchers from the German Cancer Consortium (DKTK) at Munich University Hospital (LMU) have discovered how leukemia cells cover these extra energy needs. ...

Jun 09, 2016
popularity3 comments 0

Spotting DNA repair genes gone awry

Researchers led by Ludwig Cancer Research scientist Richard Kolodner have developed a new technique for sussing out the genes responsible for helping repair DNA damage that, if left unchecked, can lead to certain cancers.

Apr 13, 2016
popularity27 comments 0

Acute myeloid leukemia (AML), also known as acute myelogenous leukemia, is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for approximately 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages.

The symptoms of AML are caused by replacement of normal bone marrow with leukemic cells, which causes a drop in red blood cells, platelets, and normal white blood cells. These symptoms include fatigue, shortness of breath, easy bruising and bleeding, and increased risk of infection. Several risk factors and chromosomal abnormalities have been identified, but the specific cause is not clear. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.

AML has several subtypes; treatment and prognosis varies among subtypes. Five-year survival varies from 15–70%, and relapse rate varies from 33-78%, depending on subtype. AML is treated initially with chemotherapy aimed at inducing a remission; patients may go on to receive additional chemotherapy or a hematopoietic stem cell transplant. Recent research into the genetics of AML has resulted in the availability of tests that can predict which drug or drugs may work best for a particular patient, as well as how long that patient is likely to survive.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Beneficial bacteria may protect breasts from cancer

Bacteria that have the potential to abet breast cancer are present in the breasts of cancer patients, while beneficial bacteria are more abundant in healthy breasts, where they may actually be protecting women from cancer, ...

Beyond the sweetness of sugar

We all know the nutritional "evils" of sugar as a potential cause of obesity, chronic disease and death, through to being a potentially brain damaging substance.

Real life brain studies: 3D brain-on-a-chip

To study brain cell's operation and test the effect of medication on individual cells, the conventional Petri dish with flat electrodes is not sufficient. For truly realistic studies, cells have to flourish within three-dimensional ...

Faster detection of pathogens in the lungs

What used to take several weeks is now possible in two days: Thanks to new molecular-based methods, mycobacterial pathogens that cause pulmonary infections or tuberculosis can now be detected much more quickly. Time-consuming ...